Revenue Increased 17% Quarter over QuarterOperating Loss Decreased 27% Management to Host Conference Call Today at 5:00 pm ETLITTLETON, Colo., ...
Vivos Therapeutics, Inc. ( NASDAQ: VVOS) Q3 2024 Earnings Conference Call November 14, 2024 5:00 PM ET Kirk Huntsman - Chariman & CEO Brad Amman - CFO Scott Henry - Alliance Global Partners Lucas Ward ...
This latest approval comes just eleven months after the FDA granted Vivos 510(k) clearance for the DNA oral appliance to treat mild-to-moderate OSA. It also marks the first time that the regulator ...
The Vivos treatment for mild-to-moderate OSA involves customized oral appliances and protocols called the Vivos System. Vivos ...
Our CARE oral medical devices are the only ... treatment options and help promote sales of its appliances. For more information, visit www.vivos.com. Cautionary Note Regarding Forward-Looking ...
Our dental and airway treatments ensure the highest standard of overall health and wellness. Dr Stock concentrates on Vivos airway treatments for children and adults, Invisalign, and restorative ...
LITTLETON, Colo., Oct. 08, 2024 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS), a medical technology company ...
Our CARE oral medical devices are ... by more than 2,000 trained dentists. The Vivos Method includes treatment regimens that employ proprietary CARE appliance therapy and other modalities that ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback